Press Releases

All Releases
View Summary AstraZeneca Advances PARP Inhibitor Into Phase 3 Trial With BRACAnalysis®
Jun 1, 2013
PDF 16.1 KB Add to Briefcase
View Summary Myriad Genetics to Present PROLARIS® Data at ASCO 2013, Continuing Its Commitment to Cancer Research
May 30, 2013
PDF 22.3 KB Add to Briefcase
View Summary Myriad Genetics to Present at the Bank of America Merrill Lynch Health Care Conference
May 14, 2013
PDF 11.8 KB Add to Briefcase
View Summary Myriad Genetics Reports Third Quarter Fiscal Year 2013 Results
May 7, 2013
PDF 26.9 KB Add to Briefcase
View Summary Myriad Genetics Announces 2013 Analyst and Investor Day
May 2, 2013
PDF 11.9 KB Add to Briefcase
View Summary Myriad to Present New Molecular Data for Patients With Prostate Cancer at the American Urological Association 2013 Annual Meeting
May 2, 2013
PDF 19.0 KB Add to Briefcase
View Summary Myriad Genetics to Announce Third Fiscal Quarter 2013 Results on Tuesday, May 7, 2013
Apr 18, 2013
PDF 13.2 KB Add to Briefcase
View Summary Myriad Adopts RainDance's Thunderstorm Platform for Next-Generation Sequencing Based Hereditary Cancer Panel
Apr 17, 2013
PDF 17.6 KB Add to Briefcase
View Summary Myriad and PharmaMar Announce First Commercial Partnership With Myriad's New HRD Test
Mar 26, 2013
PDF 16.6 KB Add to Briefcase
View Summary BRCA Testing Granted Preventive Care Designation Under the Affordable Care Act
Mar 6, 2013
PDF 16.0 KB Add to Briefcase
View Summary Myriad's Prolaris® Test Predicts Risk of Prostate Cancer Recurrence in Fourth Peer Reviewed Study
Mar 5, 2013
PDF 16.0 KB Add to Briefcase
View Summary Noridian Prices Molecular Pathology Codes; Myriad Confirms Guidance for Fiscal 2013
Mar 1, 2013
PDF 15.2 KB Add to Briefcase
View Summary Myriad Genetics Reports Second Quarter Fiscal Year 2013 Results
Feb 5, 2013
PDF 25.7 KB Add to Briefcase
View Summary Myriad Genetics to Announce Second Fiscal Quarter 2013 Results on Tuesday, February 5, 2013
Jan 15, 2013
PDF 12.3 KB Add to Briefcase
View Summary Myriad Genetics to Present at the 2013 J.P. Morgan Annual Healthcare Conference
Dec 17, 2012
PDF 12.0 KB Add to Briefcase
View Summary Myriad Announces Diabetes Collaboration With Sanofi
Dec 10, 2012
PDF 18.1 KB Add to Briefcase
View Summary Myriad Genetics' HRD Test Predicts Response to Platinum Therapy in Triple-Negative Breast Cancer
Dec 7, 2012
PDF 61.2 KB Add to Briefcase
View Summary Supreme Court of the United States to Hear Isolated DNA Patent Case
Nov 30, 2012
PDF 19.1 KB Add to Briefcase
View Summary Myriad Genetics' Prolaris Test Predicts Biochemical Recurrence in Prostate Cancer Patients Following Radiation Therapy
Nov 28, 2012
PDF 16.0 KB Add to Briefcase
View Summary Myriad Genetics to Present at the Piper Jaffray Healthcare Conference
Nov 15, 2012
PDF 12.0 KB Add to Briefcase
Showing 61-80 of 308 Page: 1 2 3 4 5 6 7 8 ... 16  Previous 20 | Next 20
Add to Briefcase = add release to Briefcase

Stock Quote (NASDAQ:MYGN)

Price:
37.12
Change:
+ 1.02
Open:
35.94
Previous Close:
36.10
Day High:
37.70
Day Low:
35.80
52 Week High:
42.50
52 Week Low:
20.02
Volume:
664,400
4:00 PM ET on Aug 1, 2014
Delayed at least 20 minutes.
Provided by eSignal.

Investor Contact

Scott Gleason
(801) 584-1143
sgleason@myriad.com

Media Contact

Ron Rogers
Corporate Communications and Media Relations
(801) 584-3065
rrogers@myriad.com